{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:44:08Z","timestamp":1757706248955},"reference-count":53,"publisher":"AACN Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:p>Methicillin-resistant Staphylococcus aureus is a frequent cause of hospital-associated infections, including central catheter\u2013associated bacteremia. Vancomycin has been the drug of choice for treating this type of bacteremia for decades in patients who have no contraindications to the antibiotic. However, resistance to vancomycin is an emerging problem. Newer antibiotics approved by the Food and Drug Administration have activity against methicillin-resistant S aureus. Some of the antibiotics also have activity against strains of S aureus that are intermediately susceptible or resistant to vancomycin. This article uses a case study to highlight the clinical signs of vancomycin failure and describes the indications for and appropriate use of alternative antimicrobials such as ceftaroline, daptomycin, linezolid, tigecycline, and telavancin. (Critical Care Nurse. 2016;36[4]:46\u201357)<\/jats:p>","DOI":"10.4037\/ccn2016475","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T08:17:39Z","timestamp":1470039459000},"page":"46-57","source":"Crossref","is-referenced-by-count":1,"title":["Treating Central Catheter\u2013Associated Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Beyond Vancomycin"],"prefix":"10.4037","volume":"36","author":[{"given":"Shannon","family":"Holt","sequence":"first","affiliation":[{"name":"Shannon Holt is an assistant professor of clinical education, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and a clinical pharmacist specialist in infectious diseases, Wake Med Health and Hospitals, Raleigh, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Thompson-Brazill","sequence":"additional","affiliation":[{"name":"Kelly Thompson-Brazill is a nurse practitioner in cardiothoracic surgery, Wake Med Health and Hospitals, a consulting associate instructor, Duke University School of Nursing, Durham, North Carolina, and a contributing editor to Critical Care Nurse."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Ryan","family":"Sparks","sequence":"additional","affiliation":[{"name":"E. Ryan Sparks is a postgraduate year 1 pharmacy practice resident at Wake Med Health and Hospitals."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Lipetzky","sequence":"additional","affiliation":[{"name":"Juliana Lipetzky is a postgraduate year 1 pharmacy practice resident at Durham VA Medical Center, Durham, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"key":"2019112612122641300_b1-0360046","volume-title":"Antibiotic Resistance Threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013"},{"issue":"suppl 5","key":"2019112612122641300_b2-0360046","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1086\/533591","article-title":"Pathogenesis of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Gordon","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2019112612122641300_b3-0360046","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2019112612122641300_b4-0360046","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/jac\/dkf009","article-title":"Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials","volume":"49","author":"Graffunder","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2019112612122641300_b5-0360046","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1017\/S0950268806006327","article-title":"Risk factors for hospital-acquired methicillin-resistant Staphylococcus aureus bacteraemia: a case-control study","volume":"134","author":"Carnicer-Pont","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"3","key":"2019112612122641300_b6-0360046","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2019112612122641300_b7-0360046","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jama.2009.153","article-title":"Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997\u20132007","volume":"301","author":"Burton","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"2019112612122641300_b8-0360046","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/497833","article-title":"Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections","volume":"41","author":"Blot","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2019112612122641300_b9-0360046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in Clin Infect Dis. 2010;150(3):457 and 2010;150(7):1079]","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019112612122641300_b10-0360046","doi-asserted-by":"crossref","DOI":"10.5600\/mmrr.003.03.a08","article-title":"Medicare non-payment of hospital-acquired infections: infection rates three years post implementation","volume":"3","author":"Peasah","year":"2013","journal-title":"Medicare Medicaid Res Rev"},{"issue":"9","key":"2019112612122641300_b11-0360046","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/cid\/cir138","article-title":"Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O\u2019Grady","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019112612122641300_b12-0360046","unstructured":"National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion. Checklist for prevention of central line associated bloodstream infections. http:\/\/www.cdc.gov\/HAI\/pdfs\/bsi\/checklist-for-CLABSI.pdf. Accessed April 19, 2016."},{"issue":"3","key":"2019112612122641300_b13-0360046","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists [published correction appears in Clin Infect Dis. 2009;49(9):1465]","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019112612122641300_b14-0360046","volume-title":"Zyvox (linezolid) [package insert]","year":"2014"},{"key":"2019112612122641300_b15-0360046","volume-title":"Cubicin (daptomycin) [package insert]","year":"2014"},{"key":"2019112612122641300_b16-0360046","volume-title":"Vibativ (telavancin) [package insert]","year":"2014"},{"key":"2019112612122641300_b17-0360046","volume-title":"Tygacil (tigecycline) [package insert]","year":"2014"},{"key":"2019112612122641300_b18-0360046","volume-title":"Teflaro (ceftaroline fosamil) [package insert]","year":"2013"},{"key":"2019112612122641300_b19-0360046","unstructured":"Redbook. Micromedex 2.0. Greenwood Village, CO: Truven Health Analytics Inc. http:\/\/www.micromedexsolutions.com. Accessed August 13, 2014."},{"issue":"6","key":"2019112612122641300_b20-0360046","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2019112612122641300_b21-0360046","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2019112612122641300_b22-0360046","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2019112612122641300_b23-0360046","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1 mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2019112612122641300_b24-0360046","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/AAC.02910-14","article-title":"Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors","volume":"58","author":"Bland","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2019112612122641300_b25-0360046","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019112612122641300_b26-0360046","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2019112612122641300_b27-0360046","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019112612122641300_b28-0360046","unstructured":"US Food Drug Administration. FDA drug safety communication: serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm265305.htm. Accessed April 20, 2016."},{"key":"2019112612122641300_b29-0360046","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"9","key":"2019112612122641300_b30-0360046","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2019112612122641300_b31-0360046","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.01402-10","article-title":"Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease","volume":"55","author":"Cai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2019112612122641300_b32-0360046","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2019112612122641300_b33-0360046","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2019112612122641300_b34-0360046","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2019112612122641300_b35-0360046","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2019112612122641300_b36-0360046","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2019112612122641300_b37-0360046","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"issue":"6","key":"2019112612122641300_b38-0360046","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate methicillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2019112612122641300_b39-0360046","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for methicillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"2019112612122641300_b40-0360046","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"issue":"7","key":"2019112612122641300_b41-0360046","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1002\/phar.1286","article-title":"Ceftaroline-induced eosinophilic pneumonia","volume":"33","author":"Desai","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2019112612122641300_b42-0360046","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1062860613486173","article-title":"Doing well by doing good: assessing the cost savings of an intervention to reduce central line-associated bloodstream infections in a Hawaii hospital","volume":"29","author":"Hsu","year":"2014","journal-title":"Am J Med Qual"},{"key":"2019112612122641300_b43-0360046","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/1471-2334-14-356","article-title":"The impact of central line insertion bundle on central line-associated bloodstream infection","volume":"14","author":"Tang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2019112612122641300_b44-0360046","unstructured":"Joint Commission. Central line insertion checklist template. In: Preventing Central Line\u2013Associated Bloodstream Infections: Useful Tools, An International Perspective. http:\/\/www.jointcommission.org\/assets\/1\/6\/CLABSI_Toolkit_Tool_3-17_Central_Line_Insertion_Checklist_-_Template.pdf. Published November 20, 2013. Accessed April 20, 2016."},{"issue":"5","key":"2019112612122641300_b45-0360046","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0897190014546115","article-title":"Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?","volume":"27","author":"Pick","year":"2014","journal-title":"J Pharm Pract"},{"issue":"3","key":"2019112612122641300_b46-0360046","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1309\/AJCPDSYS0DVLKFOH","article-title":"What proportion of vancomycin trough levels are drawn too early? frequency and impact on clinical actions","volume":"137","author":"Morrison","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2019112612122641300_b47-0360046","doi-asserted-by":"publisher","DOI":"10.1177\/0897190014568381","article-title":"Impact of nursing education on the proportion of appropriately drawn vancomycin trough concentrations [published online January 20, 2015]","author":"Coleman","journal-title":"J Pharm Pract"},{"key":"2019112612122641300_b48-0360046","unstructured":"Centers for Disease Control and Prevention. Frequently asked questions about catheter-associated bloodstream infections. http:\/\/www.cdc.gov\/hai\/pdfs\/bsi\/BSI_tagged.pdf. Accessed April 20, 2016."},{"key":"2019112612122641300_b49-0360046","volume-title":"Sivextro (tedizolid phosphate) [package insert]","year":"2014"},{"key":"2019112612122641300_b50-0360046","volume-title":"Dalvance (dalbavancin) [package insert]","year":"2014"},{"key":"2019112612122641300_b51-0360046","volume-title":"Orbactiv (oritavancin) [package insert]","year":"2014"},{"issue":"19","key":"2019112612122641300_b52-0360046","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMp1408040","article-title":"Antibiotic resistance\u2014problems, progress, and prospects","volume":"371","author":"Nathan","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2019112612122641300_b53-0360046","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Critical Care Nurse"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/36\/4\/46\/114740\/46.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/36\/4\/46\/114740\/46.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T17:45:39Z","timestamp":1574790339000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/ccnonline\/article\/36\/4\/46\/3639\/Treating-Central-CatheterAssociated-Bacteremia-Due"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.4037\/ccn2016475","relation":{},"ISSN":["0279-5442","1940-8250"],"issn-type":[{"value":"0279-5442","type":"print"},{"value":"1940-8250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}